Additional Information Regarding Influenza Virus Prevention and Control Among Specific Populations
Guidance on the Use of Influenza Antiviral Agents
The information on this page should be considered current for the 2017-2018 influenza season for clinical practice regarding the use of influenza antiviral medications. Also see the current summary of recommendations available at Influenza Antiviral Medications: Summary for Clinicians and a list of related references at Antiviral Guide References.
Each year, ACIP provides general information regarding the prevention and control of influenza. Below is additional guidance on antiviral treatment of influenza and other reports related to controlling and preventing influenza among specific populations (e.g., immunocompromised persons, health care personnel, hospital patients, pregnant women, children, and travelers) are available:
- American Academy of Pediatrics. Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2017 – 2018. 2017;140(4). Epub 2017/09/06. doi: 10.1542/peds.2017-2550. PubMed PMID: 28870977.
- American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee Opinion No. 468: Influenza vaccination during pregnancy. Obstetrics and gynecology. 2010;116(4):1006-7. Epub 2010/09/23. doi: 10.1097/AOG.0b013e3181fae845. PubMed PMID: 20859176.
- Centers for Disease Control and Prevention. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and mortality weekly report: Recommendations and reports. 2011;60(Rr-7):1-45. Epub 2011/11/24. PubMed PMID: 22108587.
- Centers for Disease Control and Prevention. Prevention Strategies for Seasonal Influenza in Healthcare Settings(https://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm).
- European Centre for Disease Prevention and Control. Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza – review of recent systematic reviews and meta-analyses. 2017; Stockholm: ECDC; 2017.
- Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations
- Food and Drug Administration. Influenza (Flu) Antiviral Drugs and Related Information.
- Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2017-18 Influenza Season. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports. 2017;66(2):1-20. Epub 2017/08/26. doi: 10.15585/mmwr.rr6602a1. PubMed PMID: 28841201.
- Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, et al. Seasonal influenza in adults and children–diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clinical infectious diseases. 2009;48(8):1003-32. Epub 2009/03/14. doi: 10.1086/598513. PubMed PMID: 19281331.
- National Institutes of Health. http://Clinicaltrials.gov Registry of federally and privately supported clinical trials conducted in the United States and around the world.
- Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health-care–associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. Morbidity and mortality weekly report: Recommendations and reports. 2004;53(Rr-3):1-36. Epub 2004/03/30. PubMed PMID: 15048056.
- World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. Geneva: World Health Organization; 2010.
- Page last reviewed: December 18, 2017
- Page last updated: December 18, 2017
- Content source:
- Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD)
- Page maintained by: Office of the Associate Director for Communication, Digital Media Branch, Division of Public Affairs